Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19-Reference-Cited by-同舟云学术

Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19

Published:2020-11-01 Issue:11 Volume:6 Page:1694
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Goldstein Daniel A.¹²,Ratain Mark J.³,Saltz Leonard B.⁴

Affiliation:

1. Davidoff Center, Rabin Medical Center, Petach Tikvah, Israel

2. Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill

3. Department of Medicine, University of Chicago, Chicago, Illinois

4. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2766704/jamaoncology_goldstein_2020_vp_200021_1604947288.52614.pdf

Reference7 articles.

1. A phamacoeconomic analysis of personalized dosing vs fixed dosing of pembrolizumab in firstline PD-L1-positive non-small cell lung cancer.;Goldstein;J Natl Cancer Inst,2017

2. A policy that encourages wastage of expensive medications—the JW modifier.;Goldstein;JAMA Oncol,2018

3. A six-weekly (Q6W) dosing schedule for pembrolizumab based on an exposure-response (E-R) evaluation using modeling and simulation.;Lala;J Clin Oncol,2018

4. Using model-based “learn and confirm” to reveal the pharmacokinetics-pharmacodynamics relationship of pembrolizumab in the KEYNOTE-001 trial.;Elassaiss-Schaap;CPT Pharmacometrics Syst Pharmacol,2017

5. Canadian Agency for Drugs and Technologies in Health. CADTH technology review: optimal use 360 report: dosing and timing of immuno-oncology drugs. Published online November 2019. Accessed May 19, 2020. https://www.cadth.ca/sites/default/files/ou-tr/ho0008-dosing-timing-immuno-oncology-drugs.pdf

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy;Basic Research in Cardiology;2024-07-22

2. Early microvascular coronary endothelial dysfunction precedes pembrolizumab-induced cardiotoxicity. Preventive role of high dose of atorvastatin;Basic Research in Cardiology;2024-03-23

3. Analysis of Medicare Expenditure for Discarded Infused Cancer Therapeutics From 2017-2020;Mayo Clinic Proceedings;2023-12

4. Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis;Respiratory Research;2023-11-14

5. Drug delivery breakthrough technologies – A perspective on clinical and societal impact;Journal of Controlled Release;2023-08